| dc.contributor.author | Spain, L | |
| dc.contributor.author | Larkin, J | |
| dc.contributor.author | Martin-Liberal, J | |
| dc.date.accessioned | 2017-04-13T09:46:34Z | |
| dc.date.issued | 2016-06-01 | |
| dc.identifier.citation | Cancer immunology, immunotherapy : CII, 2016, 65 (6), pp. 769 - 770 | |
| dc.identifier.issn | 0340-7004 | |
| dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/589 | |
| dc.identifier.eissn | 1432-0851 | |
| dc.identifier.doi | 10.1007/s00262-016-1845-2 | |
| dc.format | Print-Electronic | |
| dc.format.extent | 769 - 770 | |
| dc.language | eng | |
| dc.language.iso | eng | |
| dc.publisher | SPRINGER | |
| dc.rights.uri | https://www.rioxx.net/licenses/all-rights-reserved | |
| dc.subject | Humans | |
| dc.subject | Diabetes Mellitus | |
| dc.subject | Antibodies, Monoclonal | |
| dc.subject | Insulins | |
| dc.title | Determining predictive factors for immune checkpoint inhibitor toxicity: Response to Letter to the Editors "A case report of insulin-dependent diabetes as immune-related toxicity of pembrolizumab: presentation, management and outcome". | |
| dc.type | Journal Article | |
| dcterms.dateAccepted | 2016-05-07 | |
| rioxxterms.versionofrecord | 10.1007/s00262-016-1845-2 | |
| rioxxterms.licenseref.uri | https://www.rioxx.net/licenses/all-rights-reserved | |
| rioxxterms.licenseref.startdate | 2016-06 | |
| rioxxterms.type | Journal Article/Review | |
| dc.relation.isPartOf | Cancer immunology, immunotherapy : CII | |
| pubs.issue | 6 | |
| pubs.notes | 12 months | |
| pubs.organisational-group | /ICR | |
| pubs.organisational-group | /ICR/Primary Group | |
| pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
| pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies | |
| pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Melanoma and Kidney Cancer | |
| pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Melanoma and Kidney Cancer/Melanoma and Kidney Cancer (hon.) | |
| pubs.organisational-group | /ICR/Primary Group/Royal Marsden Clinical Units | |
| pubs.organisational-group | /ICR | |
| pubs.organisational-group | /ICR/Primary Group | |
| pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
| pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies | |
| pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Melanoma and Kidney Cancer | |
| pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Melanoma and Kidney Cancer/Melanoma and Kidney Cancer (hon.) | |
| pubs.organisational-group | /ICR/Primary Group/Royal Marsden Clinical Units | |
| pubs.publication-status | Published | |
| pubs.volume | 65 | |
| pubs.embargo.terms | 12 months | |
| icr.researchteam | Melanoma and Kidney Cancer | |
| dc.contributor.icrauthor | Spain, Lavinia | |
